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Transitional cell carcinoma of the urinary bladder is a malignancy that metastasizes frequently to lymph nodes including the
mediastinal lymph nodes. This occurrence may produce symptoms due to compression of adjacent structures such as the superior
vena cava syndrome or dysphagia from esophageal compression. We report the case of a 59-year-old man with metastatic
transitional cell carcinoma for whom mediastinal lymphadenopathy led to pulmonary artery compression and a rapidly fatal
outcome. This rare occurrence has to be distinguished from pulmonary embolism, a much more frequent event in cancer patients,
in order that proper and prompt treatment be initiated.
Copyright © 2009 Ioannis A. Voutsadakis et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Cancer is a prothrombotic condition that predisposes
patients to various thromboses such as lower extremities
thromboses and pulmonary embolism [1, 2]. Obstruction
of blood ﬂow from external compression, frequently from
lymph node masses, is also common, especially malig-
nancy of the lower abdomen and pelvis which can cause
lower extremity edema and in the mediastinum which
can cause superior vena cava syndrome from mediastinal
lymphadenopathy [3]. In contrast, compression of pul-
monary vessels from mediastinal lymphadenopathy is less
common but is important to correctly diagnose because
the treatment and prognosis are diﬀerent from those of
pulmonary embolism. We report the case of a man with
metastatic bladder carcinoma who had massive mediastinal
lymphadenopathy causing external pulmonary artery com-
pression leading to a rapidly fatal outcome.
2.CaseReport
A 59-year-old man was admitted to the hospital with severe
fatigue and dyspnea at rest. He had undergone a radical
cystectomy with neobladder construction for transitional
cell carcinoma of the urinary bladder seven months previ-
ously and had received ﬁve cycles of adjuvant dose-dense
MVAC (Methotrexate, Vinblastine, Adriamycin, and Cis-
platin) chemotherapy after the operation. A few days before
admission, restaging CTs showed multiple liver metastases,
two right kidney lesions, a lytic lesion in the thoracic
spine, massive right hilar lymphadenopathy, right pelvic
lymphadenopathy, and a right pleural eﬀusion.
On admission, the patient was pale, with dyspnea at rest,
tachypnea, and tachycardia, but he had no chest pain, cough
or hemoptysis. His blood pressure was 110/70 mmHg and
the O2 saturation was 97% when the patient was on room
air. The pO2 was 83mmHg and pCO2 was 30mmHg. No
deep vein thrombosis was clinically evident in the lower
extremities. Laboratory evaluation showed a leukocytosis at
45,000/µL with neutrophilia at 43,700/µL and lymphopenia
at 500/µL as well as a hemoglobin of 9.5gm/dL and platelets
at 66,000/µL. Other abnormal values from the biochemical
evaluation included the alkaline phosphatase at 218IU/L
(normal range 35–104IU/L), the LDH at 590IU/L (normal
range 135–225IU/L), CRP at 12.66mg/dL (normal range
0–10mg/dL), INR at 1.52, and ﬁbrinogen at 567mg/dL.2 Journal of Oncology
Figure 1: Chest X-ray showing a right middle lobe atelectasis,
bilateral inﬁltrates, and mediastinal lymphadenopathy.
L
Figure 2: CT arteriography at the carina showing occlusion of the
right pulmonary artery due to external compression from a mass
of 6.8cm and atelectasis. No intraarterial thrombus is seen. Left
pulmonary artery is nearly completely occluded from lymph node
mass of 2.3cm. Extensive mediastinal lymphadenopathy was also
seen. Pleural eﬀusions are also evident.
A chest X-ray showed right middle lobe atelectasis and
bilateral inﬁltrates (Figure 1). ECG displayed no signs of
right ventricular strain. CT angiography of pulmonary
arteries showed absence of arterial thrombi in the vessels but
conﬁrmed extensive mediastinal and hilar lymphadenopathy
obstructing and impeding blood ﬂow in both pulmonary
vessels (Figure 2). In preparation for emergency radiation
treatment, the patient had a cardiopulmonary arrest and
could not be resuscitated.
3. Discussion
The constellation of symptoms as described in this patient’s
acute presentation is suggestive of acute pulmonary
embolism, a condition not uncommon in patients with
neoplastic diseases [4]. Cancer is a prothrombotic state
and cancer patients frequently have other causes promoting
thromboses such as reduced mobility, central catheters,
and surgery [1]. In addition to pulmonary embolism due
to thrombosis, cancer patients may suﬀer from embolism
due to neoplastic emboli, a condition termed pulmonary
tumor embolism. This has been seen in up to 26% of
cancer patients in autopsy studies [5, 6] and has been
documented in transitional cell carcinoma of the bladder
[7].
Contrast-enhanced computer tomographic (CT) arteri-
ography of the pulmonary vessels and ventilation-perfusion
scintigraphy (V/Q scanning) are the studies used for diag-
nosis of pulmonary embolism [8]. Contrast-enhanced CT
arteriography has the advantage over ventilation-perfusion
scintigraphy in being able to visualize and characterize
nonvascular structures. It is also particularly useful in
the presence of pleural eﬀusions, a common occurrence
in malignancy, where V/Q scanning loses its diagnostic
accuracy. Signs of pulmonary embolism with CT arteri-
ography include intraluminal ﬁlling defects, total cutoﬀ
of vascular enhancement, enlargement of the occluded
vessel, pleural-based wedge-shaped areas with no contrast
enhancement, and linear atelectasis [8, 9]. In contrast,
CT arteriography cannot distinguish pulmonary embolism
from the rare intra-arterial tumor masses [10]. In this
case diagnosis may require intravascular sampling or
even a minithoracotomy [10]. CT arteriography in our
patient did not show pulmonary embolism but instead
revealed external pressure on the pulmonary arteries from
metastatic adenopathy, illustrating this advantage of CT
arteriography.
Lymphadenopathy compressing the circulation of lower
extremities is a common problem in patients with pelvic
malignancies while mediastinal lymphadenopathy, most
commonly from lung cancers, is a common cause of the
superior vena cava syndrome [3]. Bladder cancer has a
tendency to metastasize to intraabdominal lymph nodes,
liver,bones,andlung[11–13]whilethoraciclymphadenopa-
thy is also common although less than intraabdominal
lymphadenopathy. Mediastinal metastases from transitional
cellcarcinomaofthebladdereitherareasymptomaticormay
more commonly produce the superior vena cava syndrome
or dysphagia from esophageal invasion or compression [14].
Pulmonary arterial compression as seen in our patient is
far less common and indeed this is to the best of our
knowledge the ﬁrst case with this occurrence reported in the
English literature. Nevertheless it needs to be included in
the diﬀerential diagnosis of a cancer patient presenting with
symptoms suggestive of acute pulmonary embolism because
the treatments of the two conditions are diﬀerent. Prompt
initiation of anticoagulation is mandatory in a patient
diagnosed with pulmonary embolism while treatment for
external compression includes radiation therapy with the
possible addition of steroids to reduce concomitant soft
tissue edema and improve reactive bronchoconstriction. As
the molecular biology of metastatic bladder cancer becomes
clearer [15] and therapeutic options increase with both
conventional chemotherapy and targeted therapies [16–18],
successful management of these patients may become more
relevant.Journal of Oncology 3
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